KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Asset Writedowns and Impairment (2020 - 2023)

Historic Asset Writedowns and Impairment for Jazz Pharmaceuticals (JAZZ) over the last 6 years, with Q4 2023 value amounting to $61.0 million.

  • Jazz Pharmaceuticals' Asset Writedowns and Impairment changed N/A to $61.0 million in Q4 2023 from the same period last year, while for Dec 2023 it was $194.7 million, marking a year-over-year increase of 4565.28%. This contributed to the annual value of $61.0 million for FY2023, which is 5434.72% down from last year.
  • Jazz Pharmaceuticals' Asset Writedowns and Impairment amounted to $61.0 million in Q4 2023.
  • Over the past 5 years, Jazz Pharmaceuticals' Asset Writedowns and Impairment peaked at $136.1 million during Q1 2020, and registered a low of $61.0 million during Q4 2023.
  • For the 3-year period, Jazz Pharmaceuticals' Asset Writedowns and Impairment averaged around $110.3 million, with its median value being $133.6 million (2022).